LTZ Therapeutics Funding Round

7/30/2024

Venture Equity

$20,000,000

Series A

The company intends to use the funds to advance the development of its Myeloid Engager pipeline to treat cancer and autoimmune diseases. Proceeds from the financing will be used to accelerate development of LTZ's pipeline, supporting the company's Investigational New Drug (IND) process, initiating the Phase 1 clinical study of LTZ's lead asset LTZ-301 as well as the IND-enabling work of its second asset, LTZ-232. LTZ Therapeutics will also use the new capital to further advance other programs in discovery and to expand its team.

Private & Independent

Biopharmaceutical

1100 Island Dr. 103
Redwood City, 94065
USA

Undisclosed

LTZ Therapeutics is an immunotherapy-focused biotech company pursuing the development of novel therapies to improve clinical outcomes in patients with cancer and other diseases with an unmet clinical need. LTZ is focused on leveraging the power of innate immunity (e.g., macrophages) and elimination of immunosuppression (e.g., T regulatory cells, cancer-associated fibroblasts) as these areas have been shown to offer tremendous potential for developing innovative and effective therapies. Specifically, LTZ is developing its own novel innate engager platform to effectively activate macrophages in addition to natural killing (NK) cells as effectors to deliver direct anti-tumor and anti-immunosuppressive cell killing and promote inflammation in the tumor microenvironment -- indirectly resulting in activated adaptive immunity and long-term memory.